Bristol Myers Squibb (BMS) has exercised an option under a neuroscience research and development partnership, to obtain an exclusive US licence to Prothena’s anti-tau antibody, PRX005.
The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells’ DNA.
Israel-based Tel Aviv University (TAU)’s technology transfer company Ramot has entered a research and licence agreement with Swiss-based biopharmaceutical company Neovii to develop a vaccine against Covid-19.
Research into detecting tau proteins in the brains of Alzheimer’s patients has shown that a specific tracer could detect and measure the protein levels…